Neurocrine Biosciences reported $29M in Stock for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Stock Change
Abbvie ABBV:US $ 3483M 355M
Acadia Pharmaceuticals ACAD:US $ 7.01M 0.87M
ALKERMES ALKS:US $ 154.79M 4.45M
Alnylam Pharmaceuticals ALNY:US $ 78.52M 44.18M
Amgen AMGN:US $ 4411M 325M
Biogen BIIB:US $ 1215.4M 136.1M
Biomarin Pharmaceutical BMRN:US $ 786.36M 9.69M
Dynavax Technologies DVAX:US $ 79.04M 17.7M
Exelixis EXEL:US $ 28.47M 0.97M
Gilead Sciences GILD:US $ 2675M 1057M
Halozyme Therapeutics HALO:US $ 47.76M 6.15M
Intra Cellular Therapies ITCI:US $ 7.89M 0.06M
Nektar Therapeutics NKTR:US $ 15.38M 0.42M
Neurocrine Biosciences NBIX:US $ 29M 1.5M
Pfizer PFE:US $ 9979M 920M
Regeneron Pharmaceuticals REGN:US $ 1991.5M 488.7M
Repligen RGEN:US $ 213.78M 29.28M
Rigel Pharmaceuticals RIGL:US $ 6.76M 0.15M
Sarepta Therapeutics SRPT:US $ 199M 12.78M
Teva Pharmaceutical TEVA:IT 4.01B 194M
Ultragenyx Pharmaceutical RARE:US $ 17.81M 1.58M
Vertex Pharmaceuticals VRTX:US $ 338.9M 14.2M
YTE INCY:US $ 35.46M 7.55M